| Year |
Citation |
Score |
| 2024 |
Metge BJ, Alsheikh HAM, Kammerud SC, Chen D, Das D, Nebane NM, Bostwick JR, Shevde LA, Samant RS. Targeting EMT using low-dose Teniposide by downregulating ZEB2-driven activation of RNA polymerase I in breast cancer. Cell Death & Disease. 15: 322. PMID 38719798 DOI: 10.1038/s41419-024-06694-7 |
0.451 |
|
| 2023 |
Metge BJ, Alsheikh HA, Chen D, Elhamamsy AR, Hinshaw DC, Chen BR, Sleckman BP, Samant RS, Shevde LA. Ribosome biosynthesis and Hedgehog activity are cooperative actionable signaling mechanisms in breast cancer following radiotherapy. Npj Precision Oncology. 7: 61. PMID 37380890 DOI: 10.1038/s41698-023-00410-y |
0.374 |
|
| 2023 |
Hinshaw DC, Benavides GA, Metge BJ, Swain CA, Kammerud SC, Alsheikh HA, Elhamamsy A, Chen D, Darley-Usmar V, Rathmell JC, Welner RS, Samant RS, Shevde LA. Hedgehog Signaling Regulates Treg to Th17 Conversion Through Metabolic Rewiring in Breast Cancer. Cancer Immunology Research. 11: 687-702. PMID 37058110 DOI: 10.1158/2326-6066.CIR-22-0426 |
0.376 |
|
| 2023 |
Hinshaw DC, Swain CA, Chen D, Hanna A, Molina PA, Maynard CL, Lee G, McFarland BC, Samant RS, Shevde LA. Hedgehog blockade remodels the gut microbiota and the intestinal effector CD8 T cells in a mouse model of mammary carcinoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. 102: 1236-1244. PMID 36775449 DOI: 10.1038/s41374-022-00828-1 |
0.311 |
|
| 2022 |
Hinshaw DC, Swain CA, Chen D, Hanna A, Molina PA, Maynard CL, Lee G, McFarland BC, Samant RS, Shevde LA. Hedgehog blockade remodels the gut microbiota and the intestinal effector CD8 T cells in a mouse model of mammary carcinoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 35907952 DOI: 10.1038/s41374-022-00828-1 |
0.311 |
|
| 2021 |
Lama-Sherpa TD, Das S, Hinshaw DC, Kammerud SC, Song PN, Alsheikh HA, Sorace AG, Samant RS, Shevde LA. Quantitative longitudinal imaging reveals that inhibiting Hedgehog activity alleviates the hypoxic tumor landscape. Molecular Cancer Research : McR. PMID 34593607 DOI: 10.1158/1541-7786.MCR-21-0257 |
0.419 |
|
| 2021 |
Alsheikh HAM, Metge BJ, Pruitt HC, Kammerud SC, Chen D, Wei S, Shevde LA, Samant RS. Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors. Oncogenesis. 10: 45. PMID 34078871 DOI: 10.1038/s41389-021-00333-y |
0.514 |
|
| 2021 |
Weeks SE, Kammerud SC, Metge BJ, AlSheikh HA, Schneider DA, Chen D, Wei S, Mobley JA, Ojesina AI, Shevde LA, Samant RS. Inhibiting β-catenin disables nucleolar functions in triple-negative breast cancer. Cell Death & Disease. 12: 242. PMID 33664239 DOI: 10.1038/s41419-021-03531-z |
0.473 |
|
| 2021 |
Mota M, Metge BJ, Hinshaw DC, Alsheikh HA, Chen D, Samant RS, Shevde LA. Merlin deficiency alters the redox management program in breast cancer. Molecular Oncology. PMID 33410252 DOI: 10.1002/1878-0261.12896 |
0.439 |
|
| 2020 |
Lama-Sherpa TD, Lin VTG, Metge BJ, Weeks SE, Chen D, Samant RS, Shevde LA. Hedgehog signaling enables repair of ribosomal DNA double-strand breaks. Nucleic Acids Research. PMID 32894284 DOI: 10.1093/Nar/Gkaa733 |
0.389 |
|
| 2020 |
Samant RS, Alsheikh HA, Metge BJ, Chen D, Wei S, Shevde LA. Abstract P3-01-14: N-Myc and STAT interactor regulates STAT5a in mammary development and metastasis Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-01-14 |
0.592 |
|
| 2019 |
Weeks SE, Metge BJ, Samant RS. The nucleolus: a central response hub for the stressors that drive cancer progression. Cellular and Molecular Life Sciences : Cmls. PMID 31338556 DOI: 10.1007/S00018-019-03231-0 |
0.463 |
|
| 2019 |
Hanna A, Metge BJ, Bailey SK, Chen D, Chandrashekar DS, Varambally S, Samant RS, Shevde LA. Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. Oncoimmunology. 8: 1548241. PMID 30723576 DOI: 10.1080/2162402X.2018.1548241 |
0.51 |
|
| 2019 |
Lin VT, Lama-Sherpa TD, Samant RS, Shevde LA. Abstract 3740: Ionizing radiation-induced transcriptomic changes in triple-negative breast cancer cells reveal putative mechanisms of treatment resistance Cancer Research. 79: 3740-3740. DOI: 10.1158/1538-7445.Sabcs18-3740 |
0.517 |
|
| 2018 |
Jones KM, Karanam B, Jones-Triche J, Sandey M, Henderson HJ, Samant RS, Temesgen S, Yates C, Bedi D. Phage Ligands for Identification of Mesenchymal-Like Breast Cancer Cells and Cancer-Associated Fibroblasts. Frontiers in Oncology. 8: 625. PMID 30619759 DOI: 10.3389/Fonc.2018.00625 |
0.518 |
|
| 2018 |
Das S, Bailey SK, Metge BJ, Hanna A, Hinshaw DC, Mota M, Forero-Torres A, Chatham JC, Samant RS, Shevde LA. O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 30420690 DOI: 10.1038/S41374-018-0122-8 |
0.405 |
|
| 2018 |
Mota M, Jackson WP, Bailey SK, Vayalil P, Landar A, Rostas JW, Mulekar MS, Samant RS, Shevde LA. Deficiency of Tumor Suppressor Merlin Facilitates Metabolic Adaptation by co-operative Engagement of SMAD-Hippo Signaling in Breast Cancer. Carcinogenesis. PMID 29893810 DOI: 10.1093/Carcin/Bgy078 |
0.564 |
|
| 2018 |
Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 9: 19459. PMID 29721216 DOI: 10.18632/oncotarget.25151 |
0.345 |
|
| 2018 |
Pruitt HC, Metge BJ, Weeks SE, Chen D, Wei S, Kesterson RA, Shevde LA, Samant RS. Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors. Oncogene. PMID 29326438 DOI: 10.1038/S41388-017-0037-7 |
0.578 |
|
| 2018 |
Henderson HJ, Balasubramanyam K, Samant R, Vig K, Singh SR, Yates C, Bedi D. Abstract 25: Neuroligin 4X: A neural cell adhesion molecule, in breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-25 |
0.426 |
|
| 2018 |
Jones KM, Samant R, Singh S, Bedi D. Abstract 1078: Identification of peptides binding to mesenchymal subtype breast cancer from phage display peptide library Cancer Research. 78: 1078-1078. DOI: 10.1158/1538-7445.Am2018-1078 |
0.485 |
|
| 2017 |
Henderson HJ, Karanam B, Samant R, Vig K, Singh SR, Yates C, Bedi D. Neuroligin 4X overexpression in human breast cancer is associated with poor relapse-free survival. Plos One. 12: e0189662. PMID 29244827 DOI: 10.1371/Journal.Pone.0189662 |
0.535 |
|
| 2017 |
Goliwas KF, Richter JR, Pruitt HC, Araysi LM, Anderson NR, Samant RS, Lobo-Ruppert SM, Berry JL, Frost AR. Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model. Scientific Reports. 7: 14167. PMID 29074857 DOI: 10.1038/S41598-017-14326-8 |
0.404 |
|
| 2017 |
Lin VTG, Pruitt HC, Samant RS, Shevde LA. Developing Cures: Targeting Ontogenesis in Cancer. Trends in Cancer. 3: 126-136. PMID 28718443 DOI: 10.1016/J.Trecan.2016.12.007 |
0.476 |
|
| 2017 |
Das S, Jackson WP, Prasain JK, Hanna A, Bailey SK, Tucker JA, Bae S, Wilson LS, Samant RS, Barnes S, Shevde LA. Loss of Merlin induces metabolomic adaptation that engages dependence on Hedgehog signaling. Scientific Reports. 7: 40773. PMID 28112165 DOI: 10.1038/Srep40773 |
0.554 |
|
| 2017 |
Pruitt HC, Metge BJ, Weeks SE, Chen D, Wei S, Shevde LA, Samant RS. Abstract 1046: Conditional knockout of N-Myc and STAT Interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors Cancer Research. 77: 1046-1046. DOI: 10.1158/1538-7445.Am2017-1046 |
0.381 |
|
| 2017 |
Minata M, Alsheikh HA, Harada S, Peker D, Gillespie Y, Cerione R, Tannous B, Nakano I, Samant R, Lu S, Yamaguchi S. TMIC-07. HIGH ALDEHYDE DEHYDROGENASE ACTIVITY IDENTIFIES BRAIN METASTASIS-INITIATING CELLS IN BREAST CANCER Neuro-Oncology. 19: vi244-vi244. DOI: 10.1093/Neuonc/Nox168.997 |
0.452 |
|
| 2017 |
Alsheikh HA, Minata M, Yamaguchi S, Harada S, Peker D, Samant R, Tannous B, Bhat K, Cerione R, Zhang S, Nakano I. TMIC-31. MLK4 IS REQUIRED FOR METASTASIS INITIATION IN THE BRAIN Neuro-Oncology. 19: vi250-vi250. DOI: 10.1093/Neuonc/Nox168.1020 |
0.503 |
|
| 2016 |
Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. PMID 27888804 DOI: 10.18632/Oncotarget.13466 |
0.525 |
|
| 2016 |
Meng E, Shevde LA, Samant RS. Emerging roles and underlying molecular mechanisms of DNAJB6 in cancer. Oncotarget. PMID 27276715 DOI: 10.18632/Oncotarget.9803 |
0.42 |
|
| 2016 |
Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, Buchsbaum DJ, Samant RS, Shevde LA. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget. PMID 26908451 DOI: 10.18632/Oncotarget.7494 |
0.805 |
|
| 2016 |
Pruitt HC, Devine DJ, Samant RS. Roles of N-Myc and STAT interactor in cancer: From initiation to dissemination. International Journal of Cancer. 139: 491-500. PMID 26874464 DOI: 10.1002/Ijc.30043 |
0.768 |
|
| 2016 |
Samant RS, Pruitt HC, Metge BJ, Shevde LA. Abstract A11: N-Myc and STAT interactor (NMI): A regulator of developmental signaling and EMT Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Devbiolca15-A11 |
0.622 |
|
| 2016 |
Pruitt HC, Metge BJ, Bailey SK, Shevde LA, Samant RS. Abstract 657: N-Myc and STAT Interactor knock out in the mammary epithelium prompts hyper-proliferation Cancer Research. 76: 657-657. DOI: 10.1158/1538-7445.Am2016-657 |
0.601 |
|
| 2016 |
Samant RR, Samant RS. Abstract 1503: Discovery of new breast cancer relevant genes using the cancer genomics public database Cancer Research. 76: 1503-1503. DOI: 10.1158/1538-7445.Am2016-1503 |
0.489 |
|
| 2015 |
Yu VZ, Wong VC, Dai W, Ko JM, Lam AK, Chan KW, Samant RS, Lung HL, Shuen WH, Law S, Chan YP, Lee NP, Tong DK, Law TT, Lee VH, et al. Nuclear Localization of DNAJB6 is Associated with Survival of Patients with Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells. Gastroenterology. PMID 26302489 DOI: 10.1053/J.Gastro.2015.08.025 |
0.542 |
|
| 2015 |
Meng E, Hanna A, Samant RS, Shevde LA. The Impact of Hedgehog Signaling Pathway on DNA Repair Mechanisms in Human Cancer. Cancers. 7: 1333-48. PMID 26197339 DOI: 10.3390/Cancers7030839 |
0.381 |
|
| 2015 |
Metge BJ, Mitra A, Chen D, Shevde LA, Samant RS. N-Myc and STAT Interactor regulates autophagy and chemosensitivity in breast cancer cells. Scientific Reports. 5: 11995. PMID 26146406 DOI: 10.1038/Srep11995 |
0.594 |
|
| 2015 |
Arend RC, Gangrade A, Haygood CLW, Kurpad C, Metge BJ, Samant RS, Li P, Li Y, Bhasin D, Landen C, Alvarez R, Straughn JM, Buchsbaum DJ. Abstract POSTER-THER-1402: Overcoming platinum resistance in ovarian cancer with niclosamide Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1402 |
0.509 |
|
| 2015 |
Shevde LA, Das S, Samant RS. Abstract B40: Decoding the cellular crosstalk mediated by Hedgehog signaling in the breast tumor microenvironment Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B40 |
0.585 |
|
| 2014 |
Rostas JW, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, Singh KP, Devine DJ, Dyess DL, Richards WO, Tucker JA, Shevde LA, Samant RS. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Molecular Cancer. 13: 200. PMID 25174825 DOI: 10.1186/1476-4598-13-200 |
0.747 |
|
| 2014 |
Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecologic Oncology. 134: 112-20. PMID 24736023 DOI: 10.1016/J.Ygyno.2014.04.005 |
0.511 |
|
| 2014 |
Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Letters. 349: 8-14. PMID 24732808 DOI: 10.1016/J.Canlet.2014.04.003 |
0.444 |
|
| 2014 |
Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biology : Journal of the International Society For Matrix Biology. 37: 131-41. PMID 24657887 DOI: 10.1016/J.Matbio.2014.03.001 |
0.52 |
|
| 2014 |
Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ. Effect of niclosamide on basal-like breast cancers. Molecular Cancer Therapeutics. 13: 800-11. PMID 24552774 DOI: 10.1158/1535-7163.Mct-13-0555 |
0.564 |
|
| 2014 |
Shevde LA, Samant RS. Nonclassical hedgehog-GLI signaling and its clinical implications. International Journal of Cancer. 135: 1-6. PMID 23929208 DOI: 10.1002/Ijc.28424 |
0.425 |
|
| 2014 |
Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA, Grizzle WE, Buchsbaum DJ, Shevde LA, Samant RS. Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling. Oncogene. 33: 2620-8. PMID 23770854 DOI: 10.1038/Onc.2013.215 |
0.805 |
|
| 2014 |
Metge BJ, Mitra A, Shevde LA, Samant RS. Abstract 4046: N-myc interactor impacts autophagy via modulation of GSK3β/mTOR signaling Cancer Research. 74: 4046-4046. DOI: 10.1158/1538-7445.Am2014-4046 |
0.54 |
|
| 2014 |
Pruitt HC, Rostas JW, Metge BJ, Devine DJ, Bailey SK, Shevde LA, Samant R. Abstract 4010: MicroRNA regulator of NMI: implications for breast cancer Cancer Research. 74: 4010-4010. DOI: 10.1158/1538-7445.Am2014-4010 |
0.766 |
|
| 2014 |
Jackson WP, Kreitzburg KM, Das S, Bailey SK, Metge BJ, Samant RS, Shevde-Samant LR. Abstract 2466: The tumor suppressor Merlin decreases TGFβ/Smad signaling in metastatic breast cancer cells Cancer Research. 74: 2466-2466. DOI: 10.1158/1538-7445.Am2014-2466 |
0.608 |
|
| 2013 |
Das S, Samant RS, Shevde LA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. The Journal of Biological Chemistry. 288: 11824-33. PMID 23508962 DOI: 10.1074/Jbc.M112.432302 |
0.462 |
|
| 2013 |
Samant RS, Devine DJ, Rostas JW, Metge BJ, Shevde LA. Abstract C28: N-Myc interactor: A gatekeeper of malignant progression Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C28 |
0.814 |
|
| 2013 |
Londono-Joshi AI, Arend RC, Aristizabal L, Li Y, Lu W, Samant RS, Metge BJ, Forero A, Zhou T, LoBuglio AF, Buchsbaum DJ. Abstract 865: Inhibition of Wnt co-receptor LRP6 sensitizes basal-like breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody. Cancer Research. 73: 865-865. DOI: 10.1158/1538-7445.Am2013-865 |
0.545 |
|
| 2013 |
Arend RC, Londoño-Joshi AI, Li Y, Lu W, Samant RS, Metge BJ, Straughn JM, Buchsbaum DJ. Abstract 2179: Wnt pathway inhibition by niclosamide: a therapeutic target for ovarian cancer. Cancer Research. 73: 2179-2179. DOI: 10.1158/1538-7445.Am2013-2179 |
0.421 |
|
| 2012 |
Vincent AJ, Ren S, Harris LG, Devine DJ, Samant RS, Fodstad O, Shevde LA. Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance. Febs Letters. 586: 3429-34. PMID 22858377 DOI: 10.1016/J.Febslet.2012.07.063 |
0.744 |
|
| 2012 |
Mitra A, Rostas JW, Dyess DL, Shevde LA, Samant RS. Micro-RNA-632 downregulates DNAJB6 in breast cancer. Laboratory Investigation; a Journal of Technical Methods and Pathology. 92: 1310-7. PMID 22710984 DOI: 10.1038/Labinvest.2012.87 |
0.48 |
|
| 2012 |
Frost AR, Hurst DR, Shevde LA, Samant RS. The influence of the cancer microenvironment on the process of metastasis. International Journal of Breast Cancer. 2012: 756257. PMID 22570792 DOI: 10.1155/2012/756257 |
0.52 |
|
| 2012 |
Andrews JF, Sykora LJ, Letostak TB, Menezes ME, Mitra A, Barik S, Shevde LA, Samant RS. Cellular stress stimulates nuclear localization signal (NLS) independent nuclear transport of MRJ. Experimental Cell Research. 318: 1086-93. PMID 22504047 DOI: 10.1016/J.Yexcr.2012.03.024 |
0.714 |
|
| 2012 |
Das S, Tucker JA, Khullar S, Samant RS, Shevde LA. Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases. Plos One. 7: e34374. PMID 22479615 DOI: 10.1371/Journal.Pone.0034374 |
0.515 |
|
| 2012 |
Menezes ME, Mitra A, Shevde LA, Samant RS. DNAJB6 governs a novel regulatory loop determining Wnt/β-catenin signalling activity. The Biochemical Journal. 444: 573-80. PMID 22455953 DOI: 10.1042/Bj20120205 |
0.769 |
|
| 2012 |
Riker AI, Samant RS. Location, location, location: the BRMS1 protein and melanoma progression. Bmc Medicine. 10: 19. PMID 22356729 DOI: 10.1186/1741-7015-10-19 |
0.5 |
|
| 2012 |
Das S, Samant RS, Shevde LA. The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer. International Journal of Breast Cancer. 2012: 298623. PMID 22295244 DOI: 10.1155/2012/298623 |
0.503 |
|
| 2012 |
Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, Shevde LA, Samant RS, Dean-Colomb W, Piazza GA, Xi Y. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene. 31: 4979-86. PMID 22286762 DOI: 10.1038/Onc.2011.655 |
0.408 |
|
| 2012 |
Mitra A, Menezes ME, Pannell LK, Mulekar MS, Honkanen RE, Shevde LA, Samant RS. DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin. Oncogene. 31: 4472-83. PMID 22266849 DOI: 10.1038/Onc.2011.623 |
0.761 |
|
| 2012 |
Menezes ME, Devine DJ, Shevde LA, Samant RS. Dickkopf1: a tumor suppressor or metastasis promoter? International Journal of Cancer. 130: 1477-83. PMID 21953410 DOI: 10.1002/Ijc.26449 |
0.778 |
|
| 2012 |
Li X, Gao L, Taylor W, Shevde L, Samant R, Dean-Colomb W, Piazza GA, Xi Y. Abstract LB-172: MicroRNAs mediate the inhibition of tumor cell invasion by sulindac Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-172 |
0.416 |
|
| 2012 |
Mitra A, Menezes ME, Honkanen RE, Shevde LA, Samant RS. Abstract 2403: DNAJB6 suppresses the Wnt/β-catenin pathway Cancer Research. 72: 2403-2403. DOI: 10.1158/1538-7445.Am2012-2403 |
0.796 |
|
| 2012 |
Das S, Tucker JA, Khullar S, Samant RS, Shevde LA. Abstract 1391: Breast cancer cells and the bone: A tale of treachery Cancer Research. 72: 1391-1391. DOI: 10.1158/1538-7445.Am2012-1391 |
0.543 |
|
| 2011 |
Harris LG, Pannell LK, Singh S, Samant RS, Shevde LA. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene. 31: 3370-80. PMID 22056874 DOI: 10.1038/Onc.2011.496 |
0.554 |
|
| 2011 |
Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, Tucker JA, Samant RS, Shevde LA. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. The Journal of Biological Chemistry. 286: 40376-85. PMID 21965655 DOI: 10.1074/Jbc.M111.250035 |
0.539 |
|
| 2011 |
Harris LG, Samant RS, Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Molecular Cancer Research : McR. 9: 1165-74. PMID 21775419 DOI: 10.1158/1541-7786.Mcr-11-0175 |
0.467 |
|
| 2011 |
Das S, Samant RS, Shevde LA. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. The Journal of Biological Chemistry. 286: 9612-22. PMID 21169638 DOI: 10.1074/Jbc.M110.174920 |
0.513 |
|
| 2011 |
Menezes ME, Mitra A, Shevde LA, Samant RS. Abstract 997: Stability of β-catenin decides the tumor suppressive effect of MRJ Cancer Research. 71: 997-997. DOI: 10.1158/1538-7445.Am2011-997 |
0.775 |
|
| 2011 |
Devine DJ, Andrews J, Rostas J, Shevde LA, Samant RS. Abstract 967: N-Myc interactor, a novel regulator of EMT Cancer Research. 71: 967-967. DOI: 10.1158/1538-7445.Am2011-967 |
0.798 |
|
| 2011 |
Morrow KA, Metge BJ, Das S, Ye K, Mulekar MS, Tucker JA, Samant RS, Shevde LA. Abstract 1012: Osteopontin mediates loss of tumor suppressive activity of Merlin in breast cancer Cancer Research. 71: 1012-1012. DOI: 10.1158/1538-7445.Am2011-1012 |
0.574 |
|
| 2011 |
Harris LG, Pannell LK, Samant RS, Shevde LA. Abstract 1004: Hedgehog signaling promotes tumor vascularization, growth and metastasis of breast cancer via upregulation of CYR61 Cancer Research. 71: 1004-1004. DOI: 10.1158/1538-7445.Am2011-1004 |
0.563 |
|
| 2010 |
Mitra A, Menezes ME, Shevde LA, Samant RS. DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype. The Journal of Biological Chemistry. 285: 24686-94. PMID 20522561 DOI: 10.1074/Jbc.M109.094847 |
0.754 |
|
| 2010 |
Metge BJ, Liu S, Riker AI, Fodstad O, Samant RS, Shevde LA. Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology. 78: 75-86. PMID 20215788 DOI: 10.1159/000292363 |
0.519 |
|
| 2010 |
Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Current Molecular Medicine. 10: 71-81. PMID 20205680 DOI: 10.2174/156652410791065381 |
0.499 |
|
| 2010 |
Ren S, Liu S, Howell PM, Zhang G, Pannell L, Samant R, Shevde-Samant L, Tucker JA, Fodstad O, Riker AI. Functional characterization of the progestagen-associated endometrial protein gene in human melanoma. Journal of Cellular and Molecular Medicine. 14: 1432-42. PMID 19799645 DOI: 10.1111/J.1582-4934.2009.00922.X |
0.362 |
|
| 2010 |
Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, King JA, Samant RS. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. Journal of Cellular and Molecular Medicine. 14: 1693-706. PMID 19538464 DOI: 10.1111/J.1582-4934.2009.00821.X |
0.486 |
|
| 2010 |
Samant RS, Mitra A, Menezes ME, Shevde LA. Abstract 2289: MRJ(L) reverts mesenchymal phenotype and restricts malignancy by inhibiting Wnt/β-catenin signaling Cancer Research. 70: 2289-2289. DOI: 10.1158/1538-7445.Am10-2289 |
0.78 |
|
| 2009 |
Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS, Shevde LA. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. The Journal of Biological Chemistry. 284: 22888-97. PMID 19556240 DOI: 10.1074/Jbc.M109.021949 |
0.552 |
|
| 2009 |
Liu S, Howell P, Ren S, Fodstad O, Zhang G, Samant R, Shevde L, Xi Y, Pannell LK, Riker AI. Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clinical & Experimental Metastasis. 26: 739-49. PMID 19488830 DOI: 10.1007/S10585-009-9273-8 |
0.426 |
|
| 2009 |
Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA, Samant RS. Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. International Journal of Cancer. 125: 556-64. PMID 19358268 DOI: 10.1002/Ijc.24276 |
0.492 |
|
| 2009 |
Mitra A, Shevde LA, Samant RS. Multi-faceted role of HSP40 in cancer. Clinical & Experimental Metastasis. 26: 559-67. PMID 19340594 DOI: 10.1007/S10585-009-9255-X |
0.37 |
|
| 2009 |
Chowdhury UR, Samant RS, Fodstad O, Shevde LA. Emerging role of nuclear protein 1 (NUPR1) in cancer biology. Cancer Metastasis Reviews. 28: 225-32. PMID 19153668 DOI: 10.1007/S10555-009-9183-X |
0.549 |
|
| 2008 |
Clark DW, Mitra A, Fillmore RA, Jiang WG, Samant RS, Fodstad O, Shevde LA. NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Current Cancer Drug Targets. 8: 421-30. PMID 18690848 DOI: 10.2174/156800908785133196 |
0.393 |
|
| 2008 |
Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS, Shevde LA. Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clinical & Experimental Metastasis. 25: 753-63. PMID 18566899 DOI: 10.1007/S10585-008-9187-X |
0.54 |
|
| 2008 |
Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. Bmc Medical Genomics. 1: 13. PMID 18442402 DOI: 10.1186/1755-8794-1-13 |
0.414 |
|
| 2008 |
Xi Y, Riker A, Shevde-Samant L, Samant R, Morris C, Gavin E, Fodstad O, Ju J. Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. Cancer Genomics & Proteomics. 5: 1-35. PMID 18359977 |
0.315 |
|
| 2008 |
Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Research : Bcr. 10: R22. PMID 18328103 DOI: 10.1186/Bcr1874 |
0.508 |
|
| 2008 |
Golden T, Aragon IV, Rutland B, Tucker JA, Shevde LA, Samant RS, Zhou G, Amable L, Skarra D, Honkanen RE. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochimica Et Biophysica Acta. 1782: 259-70. PMID 18280813 DOI: 10.1016/J.Bbadis.2008.01.004 |
0.553 |
|
| 2008 |
Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR. Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. The Journal of Biological Chemistry. 283: 7438-44. PMID 18211900 DOI: 10.1074/Jbc.M709446200 |
0.482 |
|
| 2008 |
Samant RS. Breast cancer metastasis-suppressor 1 Targeted Protein Database. DOI: 10.2970/Tpdb.2008.180 |
0.487 |
|
| 2007 |
Bauer NN, Chen YW, Samant RS, Shevde LA, Fodstad O. Rac1 activity regulates proliferation of aggressive metastatic melanoma. Experimental Cell Research. 313: 3832-9. PMID 17904119 DOI: 10.1016/J.Yexcr.2007.08.017 |
0.408 |
|
| 2007 |
Samant RS, Clark DW, Fillmore RA, Cicek M, Metge BJ, Chandramouli KH, Chambers AF, Casey G, Welch DR, Shevde LA. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Molecular Cancer. 6: 6. PMID 17227585 DOI: 10.1186/1476-4598-6-6 |
0.581 |
|
| 2006 |
Hurst DR, Mehta A, Moore BP, Phadke PA, Meehan WJ, Accavitti MA, Shevde LA, Hopper JE, Xie Y, Welch DR, Samant RS. Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochemical and Biophysical Research Communications. 348: 1429-35. PMID 16919237 DOI: 10.1016/J.Bbrc.2006.08.005 |
0.424 |
|
| 2006 |
Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clinical & Experimental Metastasis. 23: 123-33. PMID 16830223 DOI: 10.1007/S10585-006-9013-2 |
0.55 |
|
| 2006 |
Samant RS, Debies MT, Hurst DR, Moore BP, Shevde LA, Welch DR. Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1). Cancer Letters. 235: 260-5. PMID 15978719 DOI: 10.1016/J.Canlet.2005.04.032 |
0.459 |
|
| 2005 |
DeWald DB, Torabinejad J, Samant RS, Johnston D, Erin N, Shope JC, Xie Y, Welch DR. Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. Cancer Research. 65: 713-7. PMID 15705865 |
0.394 |
|
| 2004 |
Kapoor P, Saunders MM, Li Z, Zhou Z, Sheaffer N, Kunze EL, Samant RS, Welch DR, Donahue HJ. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. International Journal of Cancer. Journal International Du Cancer. 111: 693-7. PMID 15252837 DOI: 10.1002/Ijc.20318 |
0.45 |
|
| 2004 |
Cicek M, Samant RS, Kinter M, Welch DR, Casey G. Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells. Clinical & Experimental Metastasis. 21: 149-57. PMID 15168732 DOI: 10.1023/B:Clin.0000024729.19084.F0 |
0.452 |
|
| 2004 |
Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR, Goldberg SF, Gilman VR, Sosnowski DM, Campo DA, Gay CV, Budgeon LR, Mercer R, Jewell J, Mastro AM, et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clinical & Experimental Metastasis. 21: 119-28. PMID 15168729 DOI: 10.1023/B:Clin.0000024763.69809.64 |
0.416 |
|
| 2004 |
Jaeger EB, Chekmareva MA, Tennant TR, Luu HH, Hickson JA, Chen SL, Samant RS, Sokoloff MH, Rinker-Schaeffer CW. Inhibition of prostate cancer metastatic colonization by ∼4.2 Mb of human chromosome 12 International Journal of Cancer. 108: 15-22. PMID 14618610 DOI: 10.1002/Ijc.11483 |
0.363 |
|
| 2004 |
Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF, Welch DR. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. The Journal of Biological Chemistry. 279: 1562-9. PMID 14581478 DOI: 10.1074/Jbc.M307969200 |
0.455 |
|
| 2002 |
Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS, Welch DR. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clinical & Experimental Metastasis. 19: 95-105. PMID 11964084 DOI: 10.1023/A:1014536909007 |
0.534 |
|
| 2002 |
Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Experimental Cell Research. 273: 229-39. PMID 11822878 DOI: 10.1006/Excr.2001.5452 |
0.464 |
|
| 2002 |
Samant RS, Debies MT, Shevde LA, Verderame MF, Welch DR. Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1). International Journal of Cancer. Journal International Du Cancer. 97: 15-20. PMID 11774238 DOI: 10.1002/Ijc.1569 |
0.368 |
|
| 2001 |
Jaeger EB, Samant RS, Rinker-Schaeffer CW. Metastasis suppression in prostate cancer. Cancer Metastasis Reviews. 20: 279-86. PMID 12085966 DOI: 10.1023/A:1015587411668 |
0.4 |
|
| 2000 |
Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan WJ, Winter CR, Christensen ND, Verderame MF, Donahue HJ, Welch DR. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clinical & Experimental Metastasis. 18: 683-93. PMID 11827072 DOI: 10.1023/A:1013124725690 |
0.461 |
|
| Show low-probability matches. |